SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Wolff AC, Davidson NE. Preoperative therapy in breast cancer: lessons from the treatment of locally advanced disease. Oncologist. 2002; 7: 239-245.
  • 2
    Kaufmann M, von Minckwitz G, Bear HD, et al. Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol. 2007; 18: 1927-1934.
  • 3
    Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary systemic therapy of breast cancer. Oncologist. 2006; 11: 574-589.
  • 4
    Gianni L, Baselga J, Eiermann W, et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res. 2005; 11: 8715-8721.
  • 5
    Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol. 1998; 9: 1179-1184.
  • 6
    Broet P, Scholl SM, de la Rochefordiere A, et al. Short and long-term effects on survival in breast cancer patients treated by primary chemotherapy: an updated analysis of a randomized trial. Breast Cancer Res Treat. 1999; 58: 151-156.
  • 7
    Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol. 1997; 15: 2483-2493.
  • 8
    Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97: 188-194.
  • 9
    Mieog JS, van der Hage JA, van de Velde CJ. Preoperative chemotherapy for women with operable breast cancer [serial online]. Cochrane Database Syst Rev. 2007;( 2): CD005002.
  • 10
    Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: 9-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001; 30: 96-102.
  • 11
    Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002; 347: 1233-1241.
  • 12
    Mirza AN, Mirza NQ, Vlastos G, Singletary SE. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow-up more than 5 years. Ann Surg. 2002; 235: 10-26.
  • 13
    Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev. 2009; 6: 339-351.
  • 14
    Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005; 353: 793-802.
  • 15
    Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000; 342: 525-533.
  • 16
    Becker S, Becker-Pergola G, Wallwiener D, Solomayer EF, Fehm T. Detection of cytokeratin-positive cells in the bone marrow of breast cancer patients undergoing adjuvant therapy. Breast Cancer Res Treat. 2006; 97: 91-96.
  • 17
    Braun S, Kentenich C, Janni W, et al. Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol. 2000; 18: 80-86.
  • 18
    Drageset V, Nesland JM, Erikstein B, et al. Monitoring of disseminated tumor cells in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. Int J Cancer. 2006; 118: 2877-2881.
  • 19
    Janni W, Hepp F, Rjosk D, et al. The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer. 2001; 92: 46-53.
  • 20
    Janni W, Rack B, Schindlbeck C, et al. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005; 103: 884-891.
  • 21
    Edge SB, Byrd DR, Compton CC, et al. eds. AJCC Cancer Staging Manual. 7th ed. New York: Springer; 2010.
  • 22
    Black MM, Speer FD. Nuclear structure in cancer tissues. Surg Gynecol Obstet. 1957; 105: 97-102.
  • 23
    Lucci A, Krishnamurthy S, Singh B, et al. Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow. Breast Cancer Res Treat. 2009; 117: 61-68.
  • 24
    Krishnamurthy S, Cristofanilli M, Singh B, et al. Detection of minimal residual disease in blood and bone marrow in early stage breast cancer. Cancer. 2010; 116: 3330-3337.
  • 25
    Hall C, Krishnamurthy S, Lodhi A, et al. Disseminated tumor cells in biologic subtypes of stage I-III breast cancer patients. Ann Surg Oncol. 2010; 17: 3252-3258.
  • 26
    Fehm T, Becker S, Becker-Pergola G, et al. Presence of apoptotic and nonapoptotic disseminated tumor cells reflects the response to neoadjuvant systemic therapy in breast cancer [serial online]. Breast Cancer Res. 2006; 8: R60.
  • 27
    Balic M, Lin H, Young L, et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res. 2006; 12: 5615-5621.
  • 28
    Braun S, Pantel K. Biological characteristics of micrometastatic cancer cells in bone marrow. Cancer Metastasis Rev. 1999; 18: 75-90.
  • 29
    Ditsch N, Mayer B, Rolle M, Untch M, Schildberg FW, Funke I. Estrogen receptor expression profile of disseminated epithelial tumor cells in bone marrow of breast cancer patients. Recent Results Cancer Res. 2003; 162: 141-147.
  • 30
    Fehm T, Krawczyk N, Solomayer EF, et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients [serial online]. Breast Cancer Res. 2008; 10: R76.
  • 31
    Krawczyk N, Banys M, Neubauer H, et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res. 2009; 29: 4019-4024.
  • 32
    Solomayer EF, Becker S, Pergola-Becker G, et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat. 2006; 98: 179-184.